Results from small studies using medications like amitriptyline and escitalopram for adults with functional dyspepsia suggest that the abdominal pain and motility may get better. "We are excited by these early findings," says Nicholas J. Talley, M.D., Ph.D., chair of the trial and Chair of the Department of Internal Medicine at the Mayo Clinic, Jacksonville, Florida. "If it turns out that these drugs correct stomach emptying, stomach retention, and overall motility, we could help improve the quality of health and life for the millions of people with functional dyspepsia."
Over the next five years, researchers will enroll 400 men and women, ages 18-75 years old with functional dyspepsia who have failed to respond to antisecretory treatments for the disorder. The participants will receive amitriptyline, or escitalopram, or placebo. Patients with peptic ulcer disease, a history of drug or alcohol abuse, and past abdominal surgeries will be excluded from the trial. Women who are pregnant and patients whose reading skills are insufficient to complete self report questionnaires will also be excluded. Recruitment for the trial began in January, 2007.
The following principal investigators and clinical centers are conducting the study:
Dr. Nicholas J. Talley, Mayo Clinic, Jacksonville, Florida (Study Chair)
Dr. John K. Dibaise, Mayo Clinic, Scottsdale, Arizona
Dr. Earnest P. Bouras, Mayo Clinic, Jacksonville, Florida
Dr. G. Richard Locke, Mayo Clinic, Rochester, Minnesota
Dr. Michael P. Jones, Northwestern University, Chicago, Illin
|Contact: Leslie Curtis|
NIH/National Institute of Diabetes and Digestive and Kidney Diseases